Following discussions in the FULL REVASC Steering Committee we believe that the results of the COMPLETE study are strong. It was a well-conducted study with clear results and no safety concerns. Patients are to be congratulated. The results will probably change practice and if so reduce new myocardial infarctions.
As of today, we have 1545 patients included in the FULL REVASC study, which is by far the largest study on FFR-guided PCI of non-culprit lesions in STEMI. The data this will generate will be of great importance and complement previous studies. However, in light of the clear COMPLETE results for tight non-culprit lesions we believe it is most ethical to temporarily pause the inclusion of more patients in the FULL REVASC study. We will discuss our options thoroughly to get the best possible plan how to move forward from here.
The follow-up of all patients included in the study will continue as planned.
We are grateful for all work with this study in all contributing countries so far, thank you!
Best regards,
Felix Böhm (Study Principal Investigator) and Stefan James (Study Chair) for the Steering Committee